{"id":111121,"date":"2024-02-27T00:00:00","date_gmt":"2024-02-27T00:00:00","guid":{"rendered":"http:\/\/indonesiatribune.com\/?guid=03545175440e1f082fef797f0a69dcd0"},"modified":"2024-02-27T00:00:00","modified_gmt":"2024-02-27T00:00:00","slug":"rok-pharmaceutical-firm-transfers-technology-of-7-products-to-vietnam","status":"publish","type":"post","link":"https:\/\/indonesiatribune.com\/rok-pharmaceutical-firm-transfers-technology-of-7-products-to-vietnam\/","title":{"rendered":"RoK pharmaceutical firm transfers technology of 7 products to Vietnam"},"content":{"rendered":"
\nHanoi: Genuone Sciences, the Republic of Korea’s leading pharmaceutical company, announced on February 26 that it signed a business agreement with Vietnam’s Imexpharm Joint Stock Company (IMP) on the transfer of technology for seven products, including medications for the treatment of cardiovascular and diabetes-related diseases.<\/p>\n
Genuone Sciences will support the entire process from production to supply and distribution of these products.<\/p>\n
In addition to the existing method of distributing domestically produced products to Vietnam, the Korean company can now produce and supply products directly in the Southeast Asian country.<\/p>\n
Samsoo Lee, CEO of Genuone Sciences Inc, described the strategic cooperation with Imexpharm as an important one that helps Genuone gradually access the Vietnamese pharmaceutical market, a potential and dynamic market in the Southeast Asia region.<\/p>\n
To date, Imexpharm owns four manufacturing clusters, including three EU-GMP manufacturing clusters with eleven production lines that meet EU
\n-GMP standards. This has made Imexpharm the largest pharmaceutical manufacturing company with EU-GMP manufacturing clusters and the highest number of EU-GMP production lines. \/.<\/p>\n
Source: Vietnam News Agency<\/p>\n","protected":false},"excerpt":{"rendered":"
Hanoi: Genuone Sciences, the Republic of Korea’s leading pharmaceutical company, announced on February 26 that it signed a business agreement with Vietnam’s Imexpharm Joint Stock Company (IMP) on the transfer of technology for seven products, includin…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"yoast_head":"\n